| Basics |
BioCryst Pharmaceuticals, Inc.
Biocryst Pharmaceuticals Inc is a pharmaceutical company that designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in the infectious and inflammatory diseases. It has its focus on oral treatments for rare diseases.
|
| IPO Date: |
March 4, 1994 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.49B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.21 | 3.04%
|
| Avg Daily Range (30 D): |
$0.12 | 1.74%
|
| Avg Daily Range (90 D): |
$0.12 | 1.50%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.55M |
| Avg Daily Volume (30 D): |
5.95M |
| Avg Daily Volume (90 D): |
3.64M |
| Trade Size |
| Avg Trade Size (Sh.): |
177 |
| Avg Trade Size (Sh.) (30 D): |
167 |
| Avg Trade Size (Sh.) (90 D): |
141 |
| Institutional Trades |
| Total Inst.Trades: |
3,894 |
| Avg Inst. Trade: |
$2.25M |
| Avg Inst. Trade (30 D): |
$1.84M |
| Avg Inst. Trade (90 D): |
$2.29M |
| Avg Inst. Trade Volume: |
.27M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.11M |
| Avg Closing Trade (30 D): |
$3.16M |
| Avg Closing Trade (90 D): |
$3.46M |
| Avg Closing Volume: |
378.57K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.05
|
$.06
|
$.02
|
|
Diluted EPS
|
$-.05
|
$.06
|
$.02
|
|
Revenue
|
$ 599.82M
|
$ 159.4M
|
$ 163.35M
|
|
Gross Profit
|
$ 584.17M
|
$ 157.21M
|
$ 160.56M
|
|
Net Income / Loss
|
$ -8.78M
|
$ 12.9M
|
$ 5.09M
|
|
Operating Income / Loss
|
$ 76.1M
|
$ 29.59M
|
$ 29.79M
|
|
Cost of Revenue
|
$ 15.65M
|
$ 2.19M
|
$ 2.8M
|
|
Net Cash Flow
|
$ 1.83M
|
$ -4.09M
|
$ -1.9M
|
|
PE Ratio
|
|
|
|
|
|
|
